Current research on how active metabolites of TCM modulate mitochondrial dysfunction in the prevention and treatment of IBD is summarized, providing new insights into the pathogenesis of the disease and opening up new avenues and strategies for the prevention, treatment, and research on IBD treatment with TCM.
Abstract
Inflammatory Bowel Disease (IBD) is a chronic relapsing inflammatory condition of the intestine, characterized by symptoms such as chronic diarrhea, abdominal pain, and weight loss. The pathogenesis of IBD is complex, with mitochondrial dysfunction being considered a key factor in its onset, progression, and persistence. Mitochondria, as the primary energy suppliers within cells, not only produce adenosine triphosphate (ATP) but also play crucial roles in regulating cellular metabolism, maintaining redox balance, and controlling cell death processes. Targeting mitochondria to regulate mitochondrial functions, including energy metabolism, oxidative stress, mitophagy, dynamics, and biogenesis, as well as maintaining the dynamic balance of the “gut microbiota-mitochondria axis,” has emerged as a promising strategy for the prevention and treatment of IBD. Traditional Chinese Medicine (TCM) has shown potential multi-target regulatory properties in preclinical studies; however, robust clinical validation and target-specific pharmacological evidence remain limited. This review explores the mechanisms and underlying connections between mitochondrial dysfunction and IBD, summarizing the current research on how active metabolites of TCM modulate mitochondrial dysfunction in the prevention and treatment of IBD. It provides new insights into the pathogenesis of the disease and opens up new avenues and strategies for the prevention, treatment, and research on IBD treatment with TCM.
Given the multifactorial nature of DCM, combination therapies targeting ferroptosis and mitochondrial dysfunction may offer superior outcomes, and future drug development should prioritize agents that precisely regulate these interrelated pathways, enabling personalized treatment strategies for DCM.
Yiting Tang, Qian Wu, Yu-Peng Chen et al.· World Journal of Diabetes· 0 citations
This review focuses on the core mechanisms that link mitochondrial dysfunction to disease progression and the major barriers to translation, and examines biomarker development and the major barriers to translation.
L. Elabbasy· Current opinion in pharmacol...· 0 citations
A path forward is proposed for integrating microbiota-targeted TCM therapies into the modern, evidence-based management of T2DM, highlighting both therapeutic potential and current challenges, such as the need for standardization.
Zhiping Ding, Qunfang Li, Z. Li et al.· Chinese Journal of Natural M...· 0 citations
This review systematically summarize the specific mitochondrial pathological phenotypes in various diseases and provides a comprehensive overview of natural products that correspond to these phenotypes, along with their mechanisms of action.
Xin-Yue Liu, Hu Li, Xuekai Wang et al.· Chinese Journal of Natural M...· 0 citations
This review summarizes the progression of cachexia research, highlighting key findings involving inflammatory cytokines, proteolytic pathways, mitochondrial dysfunction, and immune dysregulation, and novel immunomodulatory strategies, including R-ketorolac, which may restore immune homeostasis and target the root cause...
Ling-Bing Zhang, Jeffrey A. Norton· Cancers· 0 citations
Evidence showing that TFAM upregulation, whether through pharmacological interventions or genetic manipulation, consistently protects against tubular cell injury, preserves mitochondrial function, and attenuates inflammation across diverse AKI models is integrated.